Aurobindo Pharma’s wholly owned subsidiary -- Auro Vaccines has entered into a Licence agreement with Hilleman Laboratories Singapore Pte. to develop, manufacture and commercialize a pentavalent vaccine candidate used in children vaccination. Auro Vaccines will make milestone payments to Hilleman upon achieving certain development and clinical study outcomes. Hilleman will also be paid royalties upon commercialization of the vaccine candidate.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
